facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
5/2016
vol. 103
 
Share:
Share:
abstract:
Original paper

Severe cicatricial alopecia as a rare cutaneous side effect due to erlotinib – case report

Magdalena Żychowska
,
Aleksandra Batycka-Baran
,
Wojciech Baran
,
Joanna Maj

Przegl Dermatol 2016, 103, 371–375
Online publish date: 2016/10/20
View full text Get citation
 
PlumX metrics:
Introduction. Epidermal growth factor receptor inhibitors (EGFRI) are commonly used in the treatment of solid tumors. Cutaneous side effects occur in 80% of patients and are the most frequent adverse events. However, cicatricial alopecia is a rarely described side effect of EGFRI.

Objective. To present cutaneous toxicities in a patient treated with erlotinib and underscore cicatricial alopecia, rarely described in the literature.

Case report. We present a 63-year-old woman diagnosed with non-small cell lung cancer and treated with erlotinib, who developed extensive papulo-pustular eruption with severe involvement of the scalp and cicatricial alopecia. Other adverse events included trichomegaly, paronychia, granuloma pyogenicum-like lesions, dryness of the skin and pruritus.

Conclusions. Cicatricial alopecia in the presented patient may be a result of delayed introduction of dermatological treatment. Therefore, all dermatologists should be aware of treatment modalities of EGFRI-induced toxicities.
keywords:

erlotinib, alopecia, cicatricial alopecia, epidermal growth factor receptor inhibitors



Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.